Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14922350 | 0.83 | ADORA2A (0.59) | ADORA2APARP1KCNH2PARP2ADRA1B | |
| SCHEMBL2854622 | 0.81 | ADORA2A (0.42) | ADORA2AHDAC2PARP1KCNH2PARP2 | |
| SCHEMBL2847129 | 0.79 | ADORA2A (0.41) | ADORA2AHDAC1HDAC2ADRA1BADRA1D | |
| SCHEMBL2847657 | 0.77 | ADORA2A (0.46) | ADORA2A | |
| SCHEMBL2847674 | 0.75 | ADORA2A (0.59) | ADORA2A | |
| SCHEMBL2844881 | 0.74 | ADORA2A (0.75) | ADORA2A | |
| SCHEMBL2854649 | 0.73 | ADORA2A (0.56) | ADORA2A | |
| SCHEMBL2851316 | 0.73 | ADORA2A (0.56) | ADORA2A | |
| SCHEMBL2853612 | 0.73 | ADORA2A (0.58) | ADORA2A | |
| SCHEMBL2851205 | 0.73 | ADORA2A (0.58) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723343-B2 | Adenosine A2A receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7691869-B2 | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2129220-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008121748-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT,INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242672-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242672-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HDAC1 4098/4885HDAC2 4153/4885 |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HDAC1 4098/4885HDAC2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.